Frequently asked questions

DUPIXENT is indicated for the treatment of adult patients with prurigo nodularis.

It has been 9 years since initial FDA approval of DUPIXENT in atopic dermatitis in adults.^1,a

DUPIXENT has more than 1.5 million patients on therapy across approved indications worldwide.^2,b Approved indications include:

• Prurigo nodularis (18+ years of age)
• Moderate-to-severe atopic dermatitis (6+ months of age)
• Moderate-to-severe asthma (6+ years of age)
• Chronic rhinosinusitis with nasal polyps (12+ years of age)
• Eosinophilic esophagitis (1+ year of age)
• Chronic obstructive pulmonary disease (18+ years of age)
• Chronic spontaneous urticaria (2+ years of age)
• Bullous pemphigoid (18+ years of age)
• Allergic fungal rhinosinusitis (6+ years of age)

Significant itch improvement was demonstrated with DUPIXENT in PRIME and PRIME2, two phase 3, placebo-controlled, pivotal trials.^1,3

• At Week 24 in PRIME, 60% of patients treated with DUPIXENT achieved ≥4-point improvement in Worst Itch NRS vs 18% with placebo (P<0.001, primary endpoint)
• At Week 12 in PRIME2, 37% of patients treated with DUPIXENT achieved ≥4-point improvement in Worst Itch NRS vs 22% with placebo (P=0.022, primary endpoint)
  • At Week 24 in PRIME2, 58% of DUPIXENT patients achieved significant itch relief (≥4-point improvement in Worst Itch NRS) vs 20% with placebo (P<0.001, secondary endpoint)

In a pooled analysis of PRIME and PRIME2, itch improvement with DUPIXENT was observed after the first dose (as measured at Week 2).^2,4

• 7.8% of DUPIXENT patients had ≥4-point improvement in Worst Itch NRS at Week 2 vs 1.9% with placebo
• 59% of DUPIXENT patients had ≥4-point improvement in Worst Itch NRS at Week 24 vs 19% with placebo

Definitive conclusions cannot be made as this was a post hoc analysis in which data were not multiplicity controlled and P values were nominal.

See real-world itch data

DUPIXENT patients achieved significant nodule clearance at Week 24 in PRIME and PRIME2, two phase 3, placebo-controlled, pivotal trials.^1,3

• In PRIME, 48% achieved clear or almost-clear skin (≤5 nodules) vs 18% with placebo (P<0.001, secondary endpoint)
• In PRIME2, 45% achieved clear or almost-clear skin (≤5 nodules) vs 16% with placebo (P<0.001, secondary endpoint)

See real-world nodule clearance data

Prurigo nodularis is a chronic inflammatory skin disease, which you may consider treating continuously based on your clinical judgment.

The most common adverse reactions (incidence ≥2%) in adult patients with prurigo nodularis are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.¹

See more information on DUPIXENT safety

DUPIXENT has a demonstrated safety profile through Week 24 in two phase 3, placebo-controlled, pivotal trials. The most common adverse reactions (incidence ≥2%) in adult patients with prurigo nodularis are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.¹

See more information on DUPIXENT safety

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the safety or effectiveness of these vaccines. Limited data are available regarding coadministration of DUPIXENT with non-live vaccines.¹

DUPIXENT does not have a boxed warning.¹



Select Important Safety Information: Warnings and Precautions—Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

No. No initial lab testing or ongoing lab monitoring is required with DUPIXENT, according to the Prescribing Information.¹

No. DUPIXENT is not an immunosuppressant.¹

Yes, nodule clearance was assessed through 1 year in a French early access program for adults with prurigo nodularis.⁵

See nodule clearance data at 1 year

Yes, itch intensity was assessed through 1 year in a French early access program for adults with prurigo nodularis.⁵

See itch data at 1 year

DUPIXENT offers at-home and in-office administration options. DUPIXENT is administered as a subcutaneous injection every 2 weeks for adults with prurigo nodularis.¹

DUPIXENT has one dosing regimen in adults with prurigo nodularis, regardless of weight.¹

• 600 mg loading dose (2 × 300 mg SC injections), then 300 mg (1 SC injection) every 2 weeks

See more administration guidance

You can direct them to patient-friendly education and support resources available at DUPIXENT.com, which help explain biologic therapy, set expectations, and support patients throughout treatment.

Key resources include:

• Educational content on how DUPIXENT works and how it differs from traditional systemic therapies
• Step-by-step injection training videos and instructions to support at-home administration
• Patient stories and testimonials that help normalize concerns about biologic treatment
• Treatment journey and FAQ sections that address common questions about safety, dosing, and long-term use
• The DUPIXENT MyWay^® program, which offers nurse support, financial assistance information, and ongoing patient guidance

DUPIXENT has the #1 best access among specialty systemic therapies indicated for prurigo nodularis.^2,a,b

• ≈96% of commercial PN patients (18+ years of age) nationally are covered for DUPIXENT
• ≈83% of commercial patient lives have to fail only 1 or 2 prescription topical treatments

The amount your patients pay for DUPIXENT will largely depend on whether they have insurance, the type of insurance they have, whether their insurance provider considers the medication to be preferred or not preferred, and whether they’ve met their deductible.

A great place to start is with DUPIXENT MyWay^®, a patient support program that can help enable access to DUPIXENT and offers financial assistance to eligible patients, one-on-one nursing support, and more.

The DUPIXENT MyWay^® Interim Access Program assists eligible, commercially insured patients who previously started DUPIXENT and are experiencing a specific, short-term lapse in therapy. It temporarily provides eligible patients DUPIXENT at no cost, subject to program terms and conditions. You or your patients can contact DUPIXENT MyWay at 1-844-DUPIXEN(T) (1-844-387-4936) to learn more.

You can use this guide to find out about the prior authorization request and appeal process for your patients appropriate for DUPIXENT.